Tratamiento de la artritis reumatoide

  1. Movasat Hajkhan, A.
  2. Turrión Nieves, A.
  3. Bohorquez Heras, C.
  4. Pérez Gómez, A.
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2017

Título del ejemplar: Enfermedades del sistema inmune y reumatológicas (V) Artritis reumatoide, síndrome de Sjögren y uveítis

Serie: 12

Número: 28

Páginas: 1626-1638

Tipo: Artículo

DOI: 10.1016/J.MED.2017.02.011 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

Introducción La artritis reumatoide es una enfermedad sistémica caracterizada por inflamación poliarticular que conlleva un daño articular erosivo y su consecuente incapacidad funcional. Tratamiento Hoy en día, disponemos de un amplio arsenal terapéutico, constituido principalmente por fármacos modificadores de la enfermedad sintéticos y biológicos, cuyo objetivo terapéutico es conseguir la remisión de la enfermedad o, en su defecto, un bajo estado inflamatorio o actividad de la enfermedad. Práctica clínica En la práctica clínica, es necesario seguir una serie de pautas de actuación, consensuadas por expertos nacionales e internacionales, mediante las cuales se consigue controlar la enfermedad con mayor eficacia, y así evitar el daño estructural y la consecuente incapacidad.

Referencias bibliográficas

  • Mclnees IB, O`Dell JR. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis. 2010;69:1898
  • Rheumatoid arthritis. Klareskog L, Catrina AL, Paget S. Lancet. 2009;373:659.
  • Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376:1094.
  • Van Nies JA, Tsonaka Rh, Gaujoux-Viala C, Fautrel B4, van der Helmvan Mil AH. Evaluating relationships between symptom duration and persistence of rheumatoid artrhritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohort. Ann Rheum Dis. 2015;74:806.
  • Guía clínica Artritis Reumatoide. Minsal 2013-2014.
  • Aguilar MD, Carmona L, Lázaro de Mercado P, et al. Actualización de la Guía de Práctica Clínica para el manejo de la Artritis Reumatoide en España. 2007.
  • Smolen JS, Landewé R, Breedveld FC. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2013; 0:1-18.
  • Tornero J. Fármacos en el tratamiento de la artritis reumatoide. Boletín Farmacoterapéutico de Castilla-La Mancha (SESCAM). 2008;IX(5):1-8.
  • Jain R, Lipsky PE. Treatment of rheumatoid artrhritis. Med Clin North Am. 1997;81:57.
  • Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev. 2007;CD006356.
  • Sierra HA, Roganovich JM, Rizzo LFL. Glucocorticoides: paradigma de medicina traslacional de lo molecular al uso clínico. Medicina (Buenos Aires). 2012;72:158-70.
  • Verstappen SM, McCoy MJ, Roberts C, Dale NE, Hassell AB, Symmons DP; STIVEA investigators. Beneficial effects of a 3-week course of intramuscular glucocorticoid injection in patients with very early inflammatory polyarthritis: results of the STIVEA trial. Ann Rheum Dis. 2010;69:503.
  • Bohórquez A, Turrión A, Movasat A, Álvarez Mon M. Actualización en el tratamiento de la artritis reumatoide C. Medicine. 2014;11(69):4112-21.
  • Chara L, Sánchez-Atrio A, Pérez A, Cuende E, Albarrán F, Turrión A. Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis. Arthritis Res Ther. 2012;14(4):R175.
  • Cutolo M, Bolosiu H, Perdriset G; LEADER Study Group. Efficacy and safety of leflunomide in DMARD-naive patients with early rheumatoid arthritis: comparison of a loading and a fixed-dose regimen. Rheumatology (Oxford). 2013;52(6):1132-40.
  • Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gömör B. A comparision of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2000;39:655.
  • Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol. 2003;30:1182.
  • O`Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of al three medications. N Engl J Med. 1996;334:1287.
  • Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA. 2007;298:187.
  • Tam LS, Gladman DD, Hallett DC, Rahman P, Urowitz MB. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythe-matosus. J Rheumatol. 2000;27:2142.
  • Hernández C, Martínez-Prada C. Uso de fármacos modificadores de la enfermedad en artritis reumatoide. Inf Ter Nac Salud. 2009;33(4):99-109.
  • Eular Textbook on Rheumatic Disease. Edición en español; vol 3. Inflammatory arthropathies. 2014. p. 50-75.
  • Lipsky PE, Van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheu-matoid arthritis. Anti Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Anti Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343(22):1594-602.
  • St Clair EW, Van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Active controlled study of patients reciving Infliximab for the treatment of rheumatoid artrhritis of early onset study gropu. Arthritis Rheum. 2004; 50(11):3432-43.
  • Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ. Etanercept therapy in rheumatoid arthritis. A ran-domized, controlled trial. Ann Intern Med. 1999;130(6):478-86.
  • Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35-45.
  • Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26-37.
  • Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P. Golimumab, a human antitumor necrosis factor alpha monoclo-nal antibody, injected subcutaneously every four weeks in methotrexate naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo controlled study of golimumab before methotrexate as first line therapy for early onset rheumatoid arthritis. Arthritis Rheum. 2009;60(8):2272-83.
  • Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AF-TER study): a multicentre, randomised, double-blind, placebo controlled, phase III trial. Lancet. 2009;374(9685):210-21.
  • Keystone E, Heijde D, Mason D Jr, Landewé R, Vollenhoven RV, Combe B. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double blind, placebo-controlled, parallel group study. Arthritis Rheum. 2008;58(11):3319-29.
  • Smolen J, Landewé R, Mease P, Brzezicki J, Mason D, Luijtens K. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009;68(6):797-804.
  • Bresnihan B, Álvaro-García JM, Cobby M, Doherty M, Domljan Z, Emery P. Treatment of rheumatoid arthritis wiht recombinant hu-man interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41:2196-204.
  • Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo controlled trial. Arthritis Rheum. 2002;46:614-24.
  • Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double blind, placebo controlled, dose-ranging trial. Arthritis Rheum. 2006;54(5):1390-400.
  • Cohen SB, Emery P, Grennwald MW, Dougados M, Furie RA, Genovese MC. Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. REFLEX Trial Group. Arthritis Rheum. 2006;54(9):2793-806.
  • Kremer JM, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Westhovens R. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis. 2011;70(10):1826-30.
  • Genovese MC, Becher JC, Schiff M, Luggen M, Sherrer Y, Kremer J. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353(11):1114-23.
  • Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gómez-Reino JJ. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88-96.
  • Smolen J, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double blind, placebo controlled, randomised trial. OPTION Investigators. Lancet. 2008;371(9617):987-97.
  • Fleischmann RM, Halland AM, Brzosko M, Burgos-Vargas R, Mela C, Vernon E. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results. J. Rheumatol. 2013;40(2):113-26.
  • Smolen JS, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas D, Burmester G. Treating rheumatoid arthritis to target: recomendations of an international task force. Ann Rheum Dis. 2010;69:631-7.
  • Cardiel MH. Estrategia «treat to target» en la artritis reumatoide: beneficios reales. Reumatol Clin. 2013;9(2):101-5.43.
  • Sanmartía R, García-Rodríguez S, Álvaro-Gracía JM, Andreud JL, Balsa A, Cáliz R. Actualización 2014 del documento de consenso de la sociedad española de Reumatolgía sobre el uso de las terapias biológicas en la artritis reumatoide. Reumatol Clin. 2015;11(5):279-94.
  • Woolf-May K. Prescripción de ejercicio: fundamentos fisiológicos: guía para profesionales de la salud, del deporte y del ejercicio físico. Madrid: Elsevier Masson; 2008. p. 284.
  • Baillet A, Vaillant M, Guinot M, Juvin R, Gaudin P. Efficacy of resistance exercises in rheumatoid arthritis: meta-analysis of randomized controlled trials. Rheumatol Oxf Engl. 2012;51(3):519-27.
  • Robinson V, Brosseau L, Casimiro L, Judd M, Shea B, Wells G, et al Thermotherapy for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2002;(2):CD002826.
Fuente de los datos: Dialnet